Zentalis Pharmaceuticals (ZNTL)
(Delayed Data from NSDQ)
$12.54 USD
+0.02 (0.16%)
Updated May 10, 2024 04:00 PM ET
After-Market: $12.55 +0.01 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Balance Sheet
Fiscal Year End for Zentalis Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 483 | 437 | 340 | 339 | 67 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 14 | 15 | 11 | 6 | 2 |
Total Current Assets | 497 | 452 | 351 | 345 | 69 |
Net Property & Equipment | 6 | 8 | 8 | 1 | 1 |
Investments & Advances | 0 | 21 | 38 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 1 |
Intangibles | 4 | 4 | 4 | 13 | 13 |
Deposits & Other Assets | 10 | 12 | 10 | 4 | 2 |
Total Assets | 552 | 539 | 455 | 366 | 87 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 15 | 11 | 12 | 9 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 54 | 45 | 32 | 20 | 11 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 69 | 57 | 44 | 29 | 15 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 1 | 2 | 2 | 2 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 3 | 44 | 1 | 143 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 114 | 105 | 90 | 32 | 161 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 3 |
Capital Surplus | 1,324 | 1,031 | 724 | 509 | 0 |
Retained Earnings | -889 | -596 | -360 | -201 | -83 |
Other Equity | 2 | -1 | 0 | 25 | 7 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 437 | 434 | 364 | 333 | -73 |
Total Liabilities & Shareholder's Equity | 552 | 539 | 455 | 366 | 87 |
Total Common Equity | 437 | 434 | 364 | 333 | -73 |
Shares Outstanding | 70.77 | 57.07 | 45.30 | 40.60 | NA |
Book Value Per Share | 6.18 | 7.61 | 8.05 | 8.21 | 0.00 |
Fiscal Year End for Zentalis Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 489 | 483 | 517 | 553 | 393 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | 15 | 14 | 12 | 11 | 18 |
Total Current Assets | 504 | 497 | 528 | 564 | 410 |
Net Property & Equipment | 6 | 6 | 6 | 7 | 7 |
Investments & Advances | NA | 0 | 0 | 0 | 19 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | 4 | 4 | 4 | 4 | 4 |
Deposits & Other Assets | 10 | 10 | 11 | 11 | 12 |
Total Assets | 557 | 552 | 586 | 621 | 489 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | 11 | 15 | 14 | 12 | 13 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | 44 | 54 | 45 | 39 | 44 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | 55 | 69 | 59 | 52 | 56 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 1 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 2 | 2 | 2 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | 99 | 114 | 104 | 98 | 104 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,336 | 1,324 | 1,310 | 1,296 | 1,046 |
Retained Earnings | -878 | -889 | -828 | -772 | -660 |
Other Equity | 1 | 2 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 459 | 437 | 482 | 523 | 386 |
Total Liabilities & Shareholder's Equity | 557 | 552 | 586 | 621 | 489 |
Total Common Equity | 100,458 | 437 | 482 | 523 | 386 |
Shares Outstanding | 70.96 | 70.77 | 70.70 | 59.40 | 59.40 |
Book Value Per Share | 1,415.70 | 6.18 | 6.82 | 8.81 | 6.49 |